Brenntag

UBS analyst Nicole Manion has raised Brenntag’s price target from 60 to 61 euros but kept the rating at neutral. Inflationary chemical prices and supply-chain disruptions from the Middle East conflict have helped in the short term, yet upside is limited as the price boost is expected to fade in the second half of the year. Brenntag shares are up 27.5 percent year-to-date 2026; Q3 figures are expected on November 11, 2026. » More on finanzen.net

Goldman Sachs has raised its target price for Brenntag to €76 and kept its rating at "Buy", but the stock still fell about 3.1% to €59.76. In the second quarter, revenue and net profit rose significantly and management raised the full-year guidance. However, analyst consensus remains cautious (average target €57.43) and investors question whether the profit jump is sustainable. Strategically, Brenntag is shifting its business toward higher‑margin speciality chemicals via "Project Brenntag" and the acquisition of MCE Pharma; the Q3 report on November 11 is viewed as the next test. » More on de.investing.com

Brenntag reported Q2 EBITDA of €463m and H1 EBITDA of €770m and confirmed its full-year guidance of €1.45bn. Results were supported by higher prices following supply disruptions in the Middle East, while volumes remained stable. The cost-reduction program is progressing faster than planned (run-rate €41m), but working capital saw a temporary outflow of €353m. Investors cited the prospect of a weaker second half as the reason for a moderate share price decline. » More on de.investing.com